Literature DB >> 12973049

Molecular evolutionary patterns in breast cancer.

Stanley E Shackney1, Jan F Silverman.   

Abstract

Geno-phenotypic patterns of pre-invasive and invasive lobular breast cancers and infiltrating ductal carcinomas of low, intermediate, and high grade are reviewed. One of the main differences between lobular breast cancers and ductal carcinomas is the presence of inactivating E-cadherin gene mutations in lobular breast cancers. In many other respects, lobular breast cancers and low-grade ductal carcinomas exhibit similar geno-phenotypic profiles. The development of p53 dysfunction may be a hallmark of infiltrating ductal cancers of intermediate and high grade. Sequential Her-2/neu and ras abnormalities define a subset of aggressive high-grade tumors, and the development of Rb dysfunction may define a separate subset of aggressive ductal cancers. Based on these observations, a branching molecular evolutionary model for the development and progression of breast cancer is proposed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973049     DOI: 10.1097/00125480-200309000-00003

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  22 in total

1.  Evolutionary medicine: A meaningful connection between omics, disease, and treatment.

Authors:  Mones Abu-Asab; Mohamed Chaouchi; Hakima Amri
Journal:  Proteomics Clin Appl       Date:  2008-02       Impact factor: 3.494

2.  Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer.

Authors:  Ranbir Chander Sobti; Marjan Askari; Mohsen Nikbakht; Neha Singh; Suresh C Sharma; Abayneh Munshea Abitew
Journal:  Mol Cell Biochem       Date:  2012-07-19       Impact factor: 3.396

3.  Gene expression abnormalities in histologically normal breast epithelium from patients with luminal type of breast cancer.

Authors:  Pavol Zubor; Jozef Hatok; Petra Moricova; Karol Kajo; Ivana Kapustova; Andrea Mendelova; Peter Racay; Jan Danko
Journal:  Mol Biol Rep       Date:  2014-11-19       Impact factor: 2.316

4.  Stability of the HER2 gene after primary chemotherapy in advanced breast cancer.

Authors:  Zsuzsanna Varga; Rosmarie Caduff; Bernhard Pestalozzi
Journal:  Virchows Arch       Date:  2005-01-14       Impact factor: 4.064

Review 5.  Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis.

Authors:  Kenna R Mills Shaw; Carolyn N Wrobel; Joan S Brugge
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-10       Impact factor: 2.673

Review 6.  Genome evolution in ductal carcinoma in situ: invasion of the clones.

Authors:  Anna K Casasent; Mary Edgerton; Nicholas E Navin
Journal:  J Pathol       Date:  2016-11-27       Impact factor: 7.996

7.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

Authors:  Faris Farassati; Weihong Pan; Farnaz Yamoutpour; Susann Henke; Mark Piedra; Silke Frahm; Said Al-Tawil; Wells I Mangrum; Luis F Parada; Samuel D Rabkin; Robert L Martuza; Andreas Kurtz
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

8.  Predictive factors for breast cancer in patients diagnosed atypical ductal hyperplasia at core needle biopsy.

Authors:  Byung Joo Chae; Ahwon Lee; Byung Joo Song; Sang Seol Jung
Journal:  World J Surg Oncol       Date:  2009-10-23       Impact factor: 2.754

Review 9.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

10.  Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.

Authors:  Andrea Proctor Subhawong; Ty Subhawong; Hind Nassar; Nina Kouprina; Shahnaz Begum; Russell Vang; William H Westra; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2009-02       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.